HANGZHOU TIGERMED CO. H 1 (5HZ1) - Net Assets
Based on the latest financial reports, HANGZHOU TIGERMED CO. H 1 (5HZ1) has net assets worth €24.56 Billion EUR (≈ $28.72 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€28.80 Billion ≈ $33.67 Billion USD) and total liabilities (€4.24 Billion ≈ $4.95 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash flow conversion of HANGZHOU TIGERMED CO. H 1 to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €24.56 Billion |
| % of Total Assets | 85.29% |
| Annual Growth Rate | 4.16% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.81 |
HANGZHOU TIGERMED CO. H 1 - Net Assets Trend (2021–2025)
This chart illustrates how HANGZHOU TIGERMED CO. H 1's net assets have evolved over time, based on quarterly financial data. Also explore total assets of HANGZHOU TIGERMED CO. H 1 for the complete picture of this company's asset base.
Annual Net Assets for HANGZHOU TIGERMED CO. H 1 (2021–2025)
The table below shows the annual net assets of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025. For live valuation and market cap data, see 5HZ1 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €24.26 Billion ≈ $28.36 Billion |
+0.80% |
| 2024-12-31 | €24.06 Billion ≈ $28.13 Billion |
-1.59% |
| 2023-12-31 | €24.45 Billion ≈ $28.59 Billion |
+7.82% |
| 2022-12-31 | €22.68 Billion ≈ $26.52 Billion |
+10.07% |
| 2021-12-31 | €20.61 Billion ≈ $24.09 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HANGZHOU TIGERMED CO. H 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 61.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.32 Billion | 44.47% |
| Other Components | €11.64 Billion | 55.53% |
| Total Equity | €20.96 Billion | 100.00% |
HANGZHOU TIGERMED CO. H 1 Competitors by Market Cap
The table below lists competitors of HANGZHOU TIGERMED CO. H 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ehang Holdings Ltd
NASDAQ:EH
|
$501.10 Million |
|
Kaufman Et Broad
PA:KOF
|
$501.24 Million |
|
Shanghai Huide Science & Technology Co Ltd
SHG:603192
|
$501.32 Million |
|
Mesa Laboratories Inc
NASDAQ:MLAB
|
$501.65 Million |
|
Kenda Rubber Industrial Co Ltd
TW:2106
|
$500.90 Million |
|
Husqvarna AB (publ)
ST:HUSQ-A
|
$500.88 Million |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
$500.81 Million |
|
ICBC Turkey Bank AS
IS:ICBCT
|
$500.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HANGZHOU TIGERMED CO. H 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,670,653,450 to 20,959,506,515, a change of 288,853,065 (1.4%).
- Net income of 887,890,076 contributed positively to equity growth.
- Dividend payments of 343,659,038 reduced retained earnings.
- Other factors decreased equity by 255,377,973.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €887.89 Million | +4.24% |
| Dividends Paid | €343.66 Million | -1.64% |
| Other Changes | €-255.38 Million | -1.22% |
| Total Change | €- | 1.40% |
Book Value vs Market Value Analysis
This analysis compares HANGZHOU TIGERMED CO. H 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €20.77 | €3.48 | x |
| 2022-12-31 | €22.45 | €3.48 | x |
| 2023-12-31 | €24.10 | €3.48 | x |
| 2024-12-31 | €23.90 | €3.48 | x |
| 2025-12-31 | €24.34 | €3.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HANGZHOU TIGERMED CO. H 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.99%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.35x
- Recent ROE (4.24%) is below the historical average (8.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 15.86% | 55.13% | 0.22x | 1.31x | €1.06 Billion |
| 2022 | 10.25% | 28.32% | 0.26x | 1.40x | €48.25 Million |
| 2023 | 9.63% | 27.42% | 0.25x | 1.41x | €-77.83 Million |
| 2024 | 1.96% | 6.14% | 0.23x | 1.39x | €-1.66 Billion |
| 2025 | 4.24% | 12.99% | 0.24x | 1.35x | €-1.21 Billion |
Industry Comparison
This section compares HANGZHOU TIGERMED CO. H 1's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,877,950,650
- Average return on equity (ROE) among peers: -19.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | €24.56 Billion | 15.86% | 0.17x | $500.93 Million |
| IZOTROPIC CORP. (1R3) | $-4.86 Million | 0.00% | 0.00x | $10.32 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $19.89 Million | -11.18% | 0.45x | $1.06 Million |
| Check-Cap Ltd (7CC) | $23.69 Million | -74.17% | 0.06x | $8.64 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $4.13 Billion | 30.56% | 1.08x | $288.34 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $32.00 Million | -74.44% | 0.67x | $2.85 Million |
| GENINCODE PLC LS -01 (9PL) | $13.72 Million | -30.19% | 0.11x | $6.89 Million |
| INOVIQ LTD. (EGQ0) | $43.22 Million | -28.62% | 0.12x | $25.34 Million |
| Eurofins Scientific SE (ESF0) | $4.58 Billion | 10.37% | 1.40x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $8.07 Billion | 1.90% | 1.16x | $7.52 Billion |
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more